Covid-19 vaccine, GlaxoSmithKline and Sanofi start over: poor response in over-50s
GlaxoSmithKline PLC announced that its French partner Sanofi will have to return to the design phase of the Covid-19 vaccine because the draft it developed failed to elicit a strong enough response in the group most at risk, the over-50s.